Women and Heart Disease The Role of Diabetes and Hyperglycemia Elizabeth Barrett-Connor, MD; Elsa-Grace V. Giardina, MD; Anselm K. Gitt, MD; Uwe Gudat, MD; Helmut O. Steinberg, MD; Diethelm Tschoepe, MD Arch Intern Med. 2004;164:934-942.
Surgery does not deal with the basic molecular foundation of disease. It is a mechanical approach to a biologic problem. For those of us who are considered experts in the areas of coronary disease, what an embarrassment to admit that coronary artery disea
The morbidity, mortality, expense and transient benefits of a high technology approach toward the coronary disease epidemic, has failed. It is time to realize that the answer to a faulty lifestyle epidemic is not drugs and technology – it is lifestyle.
Modern cardiology has given up on curing heart disease. Its aggressive interventions-- coronary artery bypass graft, atherectomy, angioplasty, and stenting--do not reduce the frequency of new heart attacks or prolong survival except in small subsets of pa
An unreasonable gap exists between medical enthusiasm devoted to acute interventions and meager efforts devoted to secondary prevention. Rene C. Favaloro, MD, Pioneer of Coronary Artery Bypass Graft Surgery
elective PTCA of totally occluded coronary arteries is feasible but the primary success rate is lower (57%) than that associated with conventional lesions. The long-term clinical results following successful angioplasty are satisfactory (64%), but the inc
Our patient exemplified the challenges involved in a CTO, which included the length of the lesion, the lack of a proximal nipple, the presence of a side branch at the occlusion point, poor visualization of the distal vessel despite contralateral injection
An investigational drug-eluting stent called Xience, coated with everolimus, led to significantly less late lumen loss after nine months than did the Taxus (paclitaxel-eluting) stent, said researchers here today. March 2007
An investigational bioabsorbable magnesium coronary stent worked as advertised for several months but led to a higher revascularization rate at one year.
From hs-CRP results, doctors gain crucial insight into inflammation of the blood vessels around the heart, a factor not considered until now for patients at risk.
In much of the world (but not in the U.S.,) drug-coated stents are avoided by cardiologists because of their high cost. To compensate for the inability to use these stents, many cardiologists outside of the U.S. have taken to administering sirolimus (also
Finnish Medical Society Duodecim. Unstable angina pectoris. In: EBM Guidelines. Evidence-Based Medicine [CD-ROM]. Helsinki, Finland: Duodecim Medical Publications Ltd.; 2006 Mar 15 [Various]